Bennett JM (1976). “Proposals for the classification of the acute leukaemias. French-American-British（FAB）cooperative group”. Br J Haematol33 (4): 451–8. doi:10.1111/j.1365-2141.1976.tb03563.x. PMID188440.
Burkitt D (1958). “A sarcoma involving the jaws in African children”. The British journal of surgery46 (197): 218–23. doi:10.1002/bjs.18004619704. PMID13628987.
Maruyama D (2010). “Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.”. Int J Hematol.92 (5): 732-743. doi:10.1007/s12185-010-0728-0. PMID21120644.
Barnes JA (2011). “Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.”. Ann Oncol.22 (8): 1859-64. doi:10.1093/annonc/mdq677.. PMID21339382.
Coiffier B (2008). “Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.”. J Clin Oncol.26 (16): 2767-78. doi:10.1200/JCO.2007.15.0177. PMID18509186.
Peniket AJ (2003). “An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.”. Bone Marrow Transplant.31 (8): 667-678. doi:10.1038/sj.bmt.1703891. PMID12692607.
Bennett JM (1976). “Proposals for the classification of the acute leukaemias. French-American-British（FAB）cooperative group”. Br J Haematol33 (4): 451–8. doi:10.1111/j.1365-2141.1976.tb03563.x. PMID188440.
Burkitt D (1958). “A sarcoma involving the jaws in African children”. The British journal of surgery46 (197): 218–23. doi:10.1002/bjs.18004619704. PMID13628987.
“A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.”. Blood89 (11): 3909-18. (1997). PMID9166827.
Nakamura N (2002). “The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.”. Mod Pathol.15 (7): 771-776. PMID12118116.
Niwano H (1997). “An aggressive case of Burkitt's lymphoma with t(8;14) and c-myc rearrangement transformed from CD5+ B-cell lymphoma.”. Ann Hematol75: 221-225. PMID9433379.
Namiki T (2003). “Clinical and genetic characteristics of Japanese Burkitt lymphomas with or without leukemic presentation.”. Int J Hematol.77 (5): 490-498. PMID12841388.
Magrath I (1996). “Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.”. J Clin Oncol.14 (3): 925-934. PMID8622041.
Mead GM (2002). “An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.”. Ann Oncol.13 (8): 1264-74. PMID12181251.
Maruyama D (2010). “Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.”. Int J Hematol.92 (5): 732-743. doi:10.1007/s12185-010-0728-0. PMID21120644.
Thomas DA (2006). “Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.”. Cancer106 (7): 1569-80. PMID16502413.
Barnes JA (2011). “Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.”. Ann Oncol.22 (8): 1859-64. doi:10.1093/annonc/mdq677.. PMID21339382.
Bernstein JI (1986). “Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types).”. J Clin Oncol.4 (6): 847-858. PMID3711961.
Rizzieri DA (2004). “Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.”. Cancer100 (7): 1438-1448. PMID15042678.
Sweetenham JW (1996). “Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation.”. J Clin Oncol.14 (9): 2465-72. PMID8823324.
Wössmann W (2003). “Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.”. Ann Hematol.82 (3): 160-165. PMID12634948.
Coiffier B (2008). “Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.”. J Clin Oncol.26 (16): 2767-78. doi:10.1200/JCO.2007.15.0177. PMID18509186.
Peniket AJ (2003). “An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.”. Bone Marrow Transplant.31 (8): 667-678. doi:10.1038/sj.bmt.1703891. PMID12692607.
